for a more immunogenic vaccine, particularly since the individuals at highest risk for pneumococcal disease are those who exhibit the poorest immune response to polysaccharide vaccine.
Conjugation of T cell-independent polysaccharide antigens to proteins is believed to confer the properties of T cell-dependent antigens to the polysaccharide [16] [17] [18] . The immunogenicity of glycoprotein conjugate vaccines depends on several factors, including the number of doses, the amount of capsular polysaccharide per dose, the length of the polysaccharide, the type of carrier protein, and the coupling technique used [18] [19] [20] . Although we have previously shown that Haemophilus influenzae type b (Hib)-CRM I9 7 conjugate vaccine is more immunogenic than Hib polysaccharide vaccine in HIV-infected persons without AIDS [21] , there are no data on the immunogenicity of any pneumococcal conjugate vaccine in HIV-infected persons. The aims of this research were to compare the immunogenicity of a new pentavalent conjugate pneumococcal vaccine with that of a 23-valent pneumococcal polysaccharide vaccine and to evaluate the extent to which the immunodeficiency caused by HIV infection, as assessed by CD4 lymphocyte counts, modifies the immune response.
Materials and Methods
Study sites. HIV-infected persons were recruited from participants of the ALIVE (AIDS Linked to Intravenous Experience) study of injection drug users [22] , the Baltimore-Washingtonstudy site of the multicenter AIDS cohort study (MACS) of homosexual men [23] , the AIDS Clinic at the Johns Hopkins Hospital, and the Special Medicine Clinic ofthe Houston VA Medical Center. Non-HIV-infected persons (controls) included ALIVE and MACS participants and staff members of the Houston VA Medical Center. JID 1996;173 (January) Sample size. Sample size calculations, based on variance estimates of antibody levels derived from a pilot study, a significance level of .05, a power of .80, and 20% loss to follow-up, indicated that 92 persons would need to be vaccinated to detect a 2-fold difference in the geometric mean titer (GMT) of antibody or a difference of ;;.30% in the proportion of persons with a ;;.2-fold increase in titer. Because our objective was to evaluate vaccine responses in each of the 3 groups defined by HIV infection status and CD4 cell counts of ;;.2001jlL and <200IjlL, a total of 276 persons was needed.
Eligibility. Adults 18-65 years old were eligible for the study. Persons with any of the following conditions were excluded: acute febrile illness at the time of vaccination, immunization with a pneumococcal or diphtheria toxoid vaccine in the previous 5 years or a history of allergic reaction to either vaccine, a history of pneumococcal disease in the last 5 years, poor prognosis for survival in the succeeding 6 months, and pregnancy.
Vaccines. Conjugate vaccine (lot F252I04; Lederle-Praxis Biologics, Rochester, NY) consisted of 10 jlg of capsular polysaccharide, in the form of 10-20 repeating units of oligosaccharide, from each of five S. pneumoniae serotypes (6B, 14, 18C, 19F, and 23F) covalently linked to CRM 197 , a nontoxic mutant diphtheria toxin. The 23-valent pneumococcal polysaccharide vaccine (Pnu-Immune 23, lot 340941; Lederle, Wayne, NJ) is composed of25 jlg of capsular polysaccharide for each S. pneumoniae serotype. The assigned vaccine was injected into the deltoid muscle as a single dose; the subject was not informed as to which vaccine was administered.
Randomization. The Moses-Oakford algorithm and a table of random numbers were used for randomization, using randomly arranged blocks of sizes 4, 6, and 8 [24] . Randomization was stratified by HIV status (i.e., HIV-uninfected, HIV-infected with ;;.200 CD4 cells/ul., and HIV-infected with <200 CD4 cells/izl.) within each study site. CD4 cell counts, as determined by flow cytometry within the previous 6 months [25] , were used. The presence of anti-HIV antibody was ascertained by an ELISA (Genetic Systems, Seattle), with confirmation by Western blot (Du Pont, Wilmington, DE).
Ascertainment of adverse reactions. Participants were observed for 30 min after immunization for the occurrence of immediate hypersensitivity reactions. Each vaccinee was requested to record any adverse reactions for the first 7 days after immunization on a form designed for this purpose.
Samples and serologic assay. Venous blood was collected just before and 1 month after immunization. Blood samples were centrifuged within a few hours, and the resulting sera were frozen at -20°C. Serotype-specific IgG antibody to pneumococcal capsular polysaccharide was determined by ELISA [26] after sera were adsorbed with pneumococcal C-polysaccharide [27] . Each sample was tested in dilutions of 1:1000, 1:4000, and 1:16,000. The optical density was converted to micrograms per milliliter of IgG by interpolation from a calibration curve constructed with US Food and Drug Administration reference serum lot 89-S containing defined amounts of IgG antibodies to each capsular polysaccharide. The coefficients of variation ofthe assay, as assessed by a control serum (lot 89-lC), were 30%, 12%, 11%, 12%, and 16% for serotypes 6B, 14, 18C, 19F, and 23F, respectively. The paired baseline and 1-month sera of each person were assayed simultaneously, together with the reference and control sera, in the same microtiter plate.
Samples from both vaccine groups were assayed concurrently by laboratory personnel who were blinded to the vaccine assignment, HIV status, and CD4 cell counts of the participants.
Statistical analysis. The antibody titers and fold rises (i.e., postimmunization titer divided by preimmunization titer) were logtransformed to create symmetrical distributions. GMT and geometric mean fold rise were computed by taking the antilogarithm of the mean of the log-transformed titers or fold rises, respectively. Intergroup means were compared by Student's t statistic when sample variances were equal, as assessed by the F statistic; otherwise, Satterthwaite's approximation ofthe t statistic was used [28] . Intragroup means were compared by the paired t test, medians by Wilcoxon's rank sum test, and proportions by the X 2 statistic or, in case of sparse data, by Fisher's exact test. Means of > 2 groups were compared by Tukey's multiple range test [28] . All statistical tests were two-tailed.
To compare the antibody titers after immunization while adjusting for potentially confounding variables and to evaluate interactions between variables, we fitted multiple linear regression models with log (postimmunization antibody titer) as the dependent variable (PROC REG, version 6.04; SAS, Cary, NC). Enrollment site, age (years), sex, ethnic group, risk group, body mass index (kg/m"), HIV infection status, antiretroviral drug use, and vaccine type were entered as independent variables, while log (preimmunization titer) was entered as an autoregressive term to adjust for the varying preimmunization antibody titers [29] . Covariates were eliminated by a process of backward elimination, and the fit of the models was evaluated by diagnostic statistics [30] . The resulting models provide an estimate of the relative antibody response, defined as the ratio of the antibody GMTs adjusted for preimmunization titer and other confounding variables. Because the relative antibody responses are ratios, they have no units.
Results
Comparability ofstudy groups. A total of 282 persons was enrolled from July 1993 through December 1993, with 141 (50%) receiving conjugate vaccine and the remaining receiving polysaccharide vaccine. Distributions of potentially confounding variables, including enrollment site, demographic variables, risk group, body mass index, HIV infection status, CD4 cell count, antiretroviral therapy, and availability and timing of 1-month sera, were similar between the 2 vaccine groups (table  I) . Distributions of these variables and preimmunization IgG titer (figure I) within each of the three HIV infection strata were similar between the 2 vaccine groups among persons who had paired antibody results, except for mean age in HIVuninfected persons (41.9 vs. 38.0 years in conjugate and polysaccharide vaccine recipients, respectively; P < .05).
Antibody titers in HIV-uninfected persons. The postimmunization antibody titers for the five serotypes under study were significantly higher than the preimmunization titers for both conjugate and polysaccharide vaccine recipients (P < .001). For individual serotypes, the responses to conjugate vaccine could not be predicted from the responses to polysaccharide vaccine. For example, although the GMTs were similar for • Ascertained at time of enrollment unless otherwise indicated. t IVDU group includes 2 persons who were also gay and 1 who was bisexual. "Other" comprises mostly heterosexuals. Risk group of I person unknown.
: Among HIV-infected persons (92 conjugate and 91 polysaccharide vaccine recipients).
§Defined as intake of antiretroviral drug on day before or day of enrollment.
serotypes 6B and 18C after polysaccharide vaccine, the GMT was substantially greater for serotype 18C than 6B after conjugate vaccine (figure 1). The GMT at 1 month was significantlyhigher in the conjugate than the polysaccharide vaccine group for serotypes 6B (9.0 vs. 4.8 j.lg/mL, P < .05), 18C (23.2 vs. 5.9 j.lg/mL, P < .001), and 23F (15.3 vs. 4.4 j.lg/mL, P < .001) (figure 1). The increase in antibody was significantly higher after conjugate than after polysaccharide vaccine for serotypes 18C (11.8-vs. 4.0-fold, P < .001) and 23F (8.0-vs. 3.3-fold, P < .001) only (figure 1).
Antibody titers in HIV-infected persons with~200 CD4 cells/ul: A significant rise in antibody titer was observed for all serotypes in both vaccine groups, with increase in antibody to serotype 19F significantly lower in conjugate than polysaccharide vaccine groups (1.4-vs. 1.9-fold, P < .05; figure 1). However, both vaccines produced similar postimmunization GMTs for all serotypes (figure 1).
Antibody titers in HIV-infected persons with <200 CD4 cells/ul: Preimmunization GMTs were significantly lower in the group with <200 CD4 cells/nl, than in HIV-uninfected persons for serotypes 18C and 19F but was significantly higher than in the HIV-uninfected and the group with~200 CD4 cells/j.lL for serotype 14; the preimmunization GMTs were similar across the 3 HIV-CD4 cell groups for serotypes 6B and 23F. Postimmunization titers were significantly higher than preimmunization titers except for serotype 19F after conjugate vaccine. Compared with the polysaccharide vaccine group, the conjugate vaccine group had a significantly lower postimmunization GMT (1.6 vs. 3.2 j.lg/mL, P < .05) and increase in antibody (1.1-vs. 1.7-fold, P < .05) for serotype 19F (figure 1); the antibody GMTs to the other serotypes were similar between the two vaccines.
Twofold or greater rise in antibody titer. Among HIVuninfected persons, there was a significantly higher percentage with a~2-fold rise in titer (responders) in the conjugate than in the polysaccharide vaccine group for serotypes 18C (96% vs. 73%, P < .01) and 23F (90% vs. 63%, P < .01; table 2). In contrast, among HIV-infected persons with~200 CD4 cells/ j.lL, the percentage of responders was similar for the 2 vaccine groups, while in those with <200 CD4 cells/j.lL, the conjugate vaccine group had a significantly lower percentage of responders for serotype 19F than did recipients of polysaccharide vaccine (5% vs. 29%; P < .01).
Multiple linear regression analysis (relative antibody response). The relative antibody responses adjusted for preimmunization titer and other confounding variables are presented in table 3 and figure 2. Conjugate vaccine elicited substantially higher adjusted GMT levels than did polysaccharide vaccine for serotypes 6B, 18C, and 23F in HIV-uninfected but not in HIV-infected persons (P < .01 for the vaccine-HIV group interaction terms). However, no significant effect modification by HIV infection status was observed for serotypes 14 and 19F . These findings were consistent in both Baltimore and Houston, as indicated by lack of significance of the relevant interaction terms.
The antibody response to each vaccine appeared to decrease with increasing immunodeficiency. We further evaluated this phenomenon using an additional cutoff point of~500 CD4 cells/j.lL, since this cutoff has been used for grading the degree of immunodeficiency [31] . Among 19 persons with~500 CD4 cells/j.lL, the median CD4 cell counts were similar in the conjugate (n = 11) and the polysaccharide vaccinees (649 vs. 784, respectively; P = .71). Among persons receiving conjugate vaccine, the antibody response in the~500 CD4 cells/j.lLgroup was substantially lower than that in HIV-uninfected persons ( figure 2A) . In contrast, among persons receiving polysaccharide vaccine, the response in the~500 CD4 cells/zzl, group was not lower (figure 2B). 10 (24) NOTE. Data are no. (%).
* P < .01 (vs. polysaccharide vaccine).
, Median CD4 cell counts are 386/ttL for conjugate and 397/ttL for polysaccharide vaccine.
! Median CD4 cell counts are 31/ttL for conjugate and 65/ttL for polysaccharide vaccine.
Adverse reactions. Immediate hypersensitivity reactions were not observed among the vaccinees. Persons who received conjugate vaccine reported more local pain at the injection site than did those receiving polysaccharide vaccine (65% vs. 45%, P < .01). The frequencies of other reactions, including fever, redness of >2.5 em, swelling of >2.5 em, and tenderness, were similar for the two vaccines. All reactions were selflimited.
Discussion
Conjugate vaccine elicited a higher antibody response than did polysaccharide vaccine among HIV-uninfected persons for three of the five serotypes under study. However, the antibody responses elicited by the two vaccines were similar in HIVinfected persons. A decrease in response to conjugate vaccine but not to polysaccharide vaccine was apparent in subjects with CD4 cell counts of >500/pL NOTE. CI, confidence interval; data are ratio (95% CI). Data were adjusted for preimmunization titer and other variables by fitting multiple linear regression models to 262 persons with complete information (see Methods). Response to polysaccharide vaccine = I. R 2 for regression models for serotypes 6B, 14, 18C, 19F, and 23F were .64, 040, .56, .69, and .54, respectively. Vaccine-HIV group interaction terms were significant for serotypes 6B, 18C, and 23F only (P < .01).
* P < .05; t P < .001; ! P < .01 (vs. polysaccharide vaccine).
Potential limitations. It could be argued that the use of CD4 cell counts to stratify HIV-infected persons was not ideal, since CD4 cell counts are subject to biologic variation and measurement error [32] . However, our results are unlikely to be biased because randomization should distribute this potential error equally between the 2 vaccine groups.
Because immunogenicity varies by serotype, it is possible that serotypes not contained in this pentavalent conjugate vaccine could have produced different results. It is also possible that the five serotypes studied, which are responsible for the majority of invasive pneumococcal diseases in children [33] , could have elicited different antibody responses in healthy or HIV-infected children. Although the antibody responses elicited by the two pneumococcal vaccines were similar in HIV-infected persons, we cannot say with certainty that they will be equally effective in protecting against clinical disease, particularly since the potential immunologic priming elicited by conjugate vaccine may result in greater clinical efficacy [34] . Further research is needed in these areas.
Past studies. A previous study showed that HIV-infected persons with >500 CD4 cells/zzl, but not those with :0;;;500/ J-lL respond normally to pneumococcal polysaccharide vaccine [35] . Our study further strengthens this observation because we adjusted for potential confounding variables. Two previous 3-,------------------ Pneumococcal serotype studies of pneumococcal conjugate vaccines included appropriate comparison groups. A monovalent type 12F capsular polysaccharide conjugated to diphtheria toxoid elicited higher levels of antibodies to serotype 12F than polysaccharide vaccine in healthy adults [36] . Three bivalent conjugate pneumococcal vaccines, composed of capsular polysaccharides of serotypes 6B and 23F linked to CRM 197 , were studied in young children [18] . Conjugate vaccines elicited a higher antibody level than did polysaccharide vaccine for serotype 23F but not for serotype 6B.
Biologic mechanisms. Although conjugate vaccine contained 60% less polysaccharide per serotype than polysaccharide vaccine, conjugate vaccine elicited a higher antibody response than polysaccharide vaccine among HIV-uninfected persons. This may be because of the T cell-dependent properties conferred by conjugation. Likewise, HIV-induced decrease in the number and function of CD4 cells explains the impaired antibody response to conjugate vaccine in HIV-infected persons. On the other hand, response to polysaccharide vaccine was not impaired in HIV-infected persons with~500 CD4 cells/JiL, probably because these persons have an adequate number of functional B cells [35] .
We have previously shown that Hib-CRM 197 conjugate vaccine is more immunogenic than Hib polysaccharide vaccine in HIV-infected persons without AIDS [21] . The comparatively greater immunogenicity of Hib conjugate vaccine may have resulted from the inherently greater immunogenicity of Hib capsular polysaccharide, differences in the ratio of the polysaccharide to the carrier protein or in conformational epitopes, or other factors. However, it is possible that the immunogenicity of pneumococcal conjugate vaccine can be enhanced by varying the formulation of the vaccine.
Practical implications. Our findings have several practical implications. First, the antibody responses of adults elicited by conjugate vaccine could not be predicted from the response to the corresponding serotype in polysaccharide vaccine. This observation highlights the need to evaluate the immunogenicity of each serotype that will be ultimately included in a polyvalent pneumococcal conjugate vaccine. Second, this conjugate vaccine elicited a higher antibody response than polysaccharide vaccine in HIV-uninfected but not in HIV-infected persons. This finding is important, as it suggests the need to evaluate newer pneumococcal vaccines in all high-risk groups for whom pneumococcal immunization is recommended. Third, the observation that the antibody response to polysaccharide vaccine in HIV-infected persons is impaired only when CD4 cell counts fall below 500/ILL underscores the need to immunize HIVinfected persons early in the course of their infection with currently available polysaccharide vaccines. Finally, the finding that even some severely immunodeficient persons respond to immunization (table 2) suggests that persons who have a delayed diagnosis of HIV infection can benefit from these vaccines.
